Buccal Testosterone Composition for Sustained Zero-Order Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering testosterone, such as oral, intramuscular, transdermal, and subcutaneous administration, face challenges in maintaining therapeutic levels due to first-pass metabolism, physical size limitations, and patient compliance issues, particularly in achieving a substantially zero-order release pattern over extended periods.
Innovation Solution
A trans-mucosal delivery system is developed using an aqueous phase with humectants and an oil phase containing testosterone and surfactants, mixed at specific ratios to form a hydrophobic composition that provides sustained release properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If testosterone is administered orally in bonded form (testosterone undecanoate, methyltestosterone, or testosterone cyclodextrin), then first-pass metabolism is avoided, but the drug must be taken multiple times daily and requires food consumption
Solution Approach 1:
The patent changes the physical-chemical parameters of testosterone by converting it from bonded forms back to native free testosterone form. This parameter change enables the drug to achieve sustained release through trans-mucosal delivery, reducing administration frequency from multiple times daily to once daily while avoiding first-pass metabolism through buccal absorption
Solution Approach 2:
The patent introduces a trans-mucosal delivery system as an intermediary between the drug and systemic circulation. This delivery system uses buccal mucosa as an intermediate absorption site that bypasses the gastrointestinal tract and liver first-pass metabolism, allowing direct entry into systemic circulation
2Speed
If testosterone esters are administered by intramuscular injection, then absorption is slower compared to free testosterone, but no rate-controlling mechanism is provided and substantially zero order release pattern cannot be achieved
Solution Approach 1:
The patent changes the formulation parameters by creating a specific oil-based suspension system with controlled viscosity and particle size distribution. This parameter control provides a rate-controlling mechanism that achieves substantially zero order release pattern over 24 hours, unlike intramuscular esters that lack such control
3Reliability
If transdermal delivery systems are used, then first-pass hepatic metabolism is avoided, but the physical size requires frequent device replacement every few days leading to fluctuations in serum testosterone levels
Solution Approach 1:
The patent creates a buccal delivery system that copies the successful first-pass avoidance strategy of transdermal delivery but applies it to a different mucosal site. The buccal route provides the same metabolic advantage while enabling longer duration of action through sustained release from the oil-based formulation, eliminating the need for frequent device replacement
4Ease of operation
If subcutaneous implants of testosterone-loaded pellets are used, then therapy extends to several months improving compliance, but surgical procedure is required for insertion and removal with risks of infection, pain and swelling
Solution Approach 1:
The patent employs a disposable buccal delivery system that is inserted and removed without surgical intervention. The system is designed for short-term use (24 hours) but can be repeated daily, achieving sustained therapy through simple self-administration rather than permanent implantation, thereby eliminating surgical risks while maintaining compliance
5Ease of manufacture
If native form of testosterone is administered, then manufacturing process is simpler and less expensive, but sustained release properties are needed to reduce multiple daily doses
Solution Approach 1:
The patent creates a composite formulation by combining native testosterone with specific oils and surfactants. This composite material provides sustained release properties through the oil-based matrix while maintaining the simplicity of using native testosterone, achieving both manufacturing ease and reduced dosage frequency through the synergistic combination of materials
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves sustained therapeutic testosterone levels for 12-24 hours with daily use and up to 10 hours in animals, offering a convenient and effective alternative to existing methods.
Implementation Method 1
an oil phase comprising testosterone in the range of about 0.001 to 25.0 wt. %, optionally at least one surfactant
Implementation Method 2
an aqueous phase containing water and at least one humectant
Data Source
AI summary
A trans-mucosal testosterone delivery composition for humans or animals having from about 50 to 99 wt. % humectant, from about 1 to 50 wt. % water, from about 0.001 to 25.00 wt. % testosterone, from about 0 to 25 wt. % oil, and from about 25 to 1 wt. % surfactant, wherein the composition is hydrophobic and has release properties.